ADC Therapeutics Submits its First IND

ADC Therapeutics Sarl, the oncology drug development company focused on Antibody Drug Conjugates “ADCs”, today announced that it has filed an Investigational New Drug application “IND” with the US Food and Drug Administration as it moves its pipeline into clinical development. The IND is for a Phase I clinical trial for ADCT-301, a novel antibody drug conjugate targeting CD25, a cell-surface antigen, which is over-expressed in many patients with lymphomas.

Read the full press release